Also enhanced draining of antigens loaded by DC leads to better efficacy when VEGF-C is combined with other treatments, including cytotoxic T lymphocyte-associated protein 4 (CTLA-4), the PD-1 blockade and radiotherapy in mice bearing GBM [30–32]. The gene discussed is CTLA4; the disease is glioblastoma.